Apel­lis nabs pri­or­i­ty re­view for ge­o­graph­ic at­ro­phy pitch; Bris­tol My­ers ex­tends of­fer time­line on Turn­ing Point buy­out

The FDA will de­cide by Nov. 26 whether to ap­prove the first treat­ment for ge­o­graph­ic at­ro­phy sec­ondary to age-re­lat­ed mac­u­lar de­gen­er­a­tion, an ir­re­versible dis­ease that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER